BioXcel Therapeutics, Inc.
BTAI
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new tā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.00
Price-1.96%
-$0.04
1Y
Price
Market Cap
$43.739m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-27003.1%
EBITDA Margin-31541.8%
Net Profit Margin-19170.4%
Free Cash Flow Margin-27003.1%
EBITDA Margin-31541.8%
Net Profit Margin-19170.4%
Free Cash Flow MarginRevenue
$752k
-66.8%
1y CAGR+88.5%
3y CAGR+66.4%
5y CAGREarnings
-$68.211m
-14.4%
1y CAGR+14.8%
3y CAGR-2.7%
5y CAGREPS
-$9.70
+58.7%
1y CAGR+43.7%
3y CAGR+21.3%
5y CAGRBook Value
-$88.919m
$44.792m
Assets$133.711m
Liabilities$109.286m
DebtDebt to Assets
244.0%
-2.1x
Debt to EBITDAFree Cash Flow
-$58.214m
+19.2%
1y CAGR+19.4%
3y CAGR-1.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company